Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
Phase of Trial: Phase IV
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Apixaban (Primary)
- Indications Atrial fibrillation; Stroke
- Focus Therapeutic Use
- Acronyms AEGEAN
- Sponsors Bristol-Myers Squibb
- 16 Nov 2016 Results of adherence and persistence to apixaban treatment presented at the 89th Annual Scientific Sessions of the American Heart Association
- 09 Sep 2016 Status changed from active, no longer recruiting to completed.
- 03 May 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016.